Welcome to our dedicated page for 180 Life Sciences news (Ticker: ATNF), a resource for investors and traders seeking the latest updates and insights on 180 Life Sciences stock.
ETHZilla Corporation, formerly 180 Life Sciences Corp. (ATNF), reports developments tied to its transition from a biotechnology and iGaming-focused issuer into a public-company Ethereum treasury vehicle. Recurring updates cover ETH accumulation, treasury financing, convertible notes, private placements, common stock and warrant ticker changes, and the company’s on-chain yield strategy with Electric Capital as external asset manager.
Company news also covers legacy operating matters, including biotechnology intellectual property in areas such as neuroinflammation, fibrosis and post-operative cognitive dysfunction, as well as the Technology Gaming Platform associated with the company’s iGaming strategy. Capital-structure actions, share repurchases, governance changes and strategic updates remain recurring disclosure themes.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
180 Life Sciences Corp. (NASDAQ: ATNF) announced the closing of its registered direct offering, selling 1,570,680 shares of common stock and warrants, generating approximately $3 million in gross proceeds. The shares were priced at $1.91 each, with warrants allowing purchase at $1.78. The net proceeds will fund research and development expenses, including a marketing authorization application.
A.G.P./Alliance Global Partners acted as the placement agent. The offering is based on an effective shelf registration statement with the SEC filed previously. Additionally, existing warrants for 2,878,032 shares will be amended to lower the exercise price to $1.78 and extend the expiration.